

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee
02/20 *577517*

In accordance with the letter dated
May 11, 2012,

1. Daviess Community Hospital

3. License No. 13-16138-01

is amended in its entirety to read as follows:

2. 1314 East Walnut

4. Expiration Date: April 30, 2021

P.O. Box 760

5. Docket No. 030-10475

Washington, Indiana 47501

Reference No.

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material permitted by 10 CFR 35.100

A. Any

A. As needed

B. Any byproduct material permitted by 10 CFR 35.200

B. Any

B. As needed

C. Any byproduct material permitted by 10 CFR 35.300

C. Any

C. As needed, not to exceed one curie of Iodine-131

D. Any byproduct material permitted by 10 CFR 31.11

D. Prepackaged Kits

D. 5 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. In vitro studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 1314 East Walnut, Washington, Indiana.

11. The Radiation Safety Officer (RSO) for this license is Vasdev Lohano, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.
13-16138-01

Docket or Reference No.
030-10475

Amendment No. 22

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized User

Material and Use

Vasdev Lohano, M.D.

10 CFR 35.300 limited to oral administration of sodium iodide I-131 for any uptake, dilution and excretion study or therapy procedure in quantities less than or equal to 33 millicuries.

James A. Arata, M.D.

10 CFR 35.100 and 35.200.

Jonathon Berger, M.D.

10 CFR 35.100 and 35.200.

John L. Bormann, M.D.

10 CFR 35.100 and 35.200.

Daniel Branam, M.D.

10 CFR 35.100 and 35.200.

Richard B. Collins, D.O.

10 CFR 35.100 and 35.200.

Joseph R. Decamp, M.D.

10 CFR 35.100 and 35.200.

Jeffrey J. Freeman, M.D.

10 CFR 35.100 and 35.200.

Brett A. Hagedorn, M.D.

10 CFR 35.100 and 35.200.

Eric V. Heatwole, M.D.

10 CFR 35.100 and 35.200.

Linda Gould Hippenhammer, M.D.

10 CFR 35.100 and 35.200.

David B. Janizek, M.D.

10 CFR 35.100 and 35.200.

Shawn Johnson, M.D.

10 CFR 35.100 and 35.200.

Shilpa Kashyap, M.D.

10 CFR 35.100 and 35.200.

Christopher Michael Kowalski, M.D.

10 CFR 35.100 and 35.200.

John C. Lacunza, M.D.

10 CFR 35.100 and 35.200.

Michael E. Parker, M.D.

10 CFR 35.100 and 35.200.

John Pasalich, M.D.

10 CFR 35.100 and 35.200.

Dakshesh S. Patel, M.D.

10 CFR 35.100 and 35.200.

Stephen R. Phillip, M.D.

10 CFR 35.100 and 35.200.

Randall J. Phillips, M.D.

10 CFR 35.100 and 35.200.

John Rock, M.D.

10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.
13-16138-01

Docket or Reference No.
030-10475

Amendment No. 22

| <u>Authorized User</u> | <u>Material and Use</u> |
|------------------------------|---------------------------|
| Eugene Shih, M.D. | 10 CFR 35.100 and 35.200. |
| Richard W. Sibley, M.D. | 10 CFR 35.100 and 35.200. |
| Rik Stephens, M.D. | 10 CFR 35.100 and 35.200. |
| Andre Byard Stovall, M.D. | 10 CFR 35.100 and 35.200. |
| Pamela Lee Strange, M.D. | 10 CFR 35.100 and 35.200. |
| Marc Thomas, M.D. | 10 CFR 35.100 and 35.200. |
| Christine Anne Tremper, M.D. | 10 CFR 35.100 and 35.200. |
| Frederick N. Vandeman, M.D. | 10 CFR 35.100 and 35.200. |
| James C. Wehrenberg, M.D. | 10 CFR 35.100 and 35.200. |

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated October 4, 2010; and
- B. Letter dated March 30, 2011.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date JUN 21 2012

By


Bryan A. Parker
Materials Licensing Branch
Region III